Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of FOLFOX + Panitumumab & Colorectal Cancer (CRC) (EGFR m), FOLFOX + Panitumumab is approved by both FDA and EMA for RAS wild‑type metastatic Colorectal Cancer (CRC) (EGFR m) (1)
Reinduction strategies with anti-EGFR-based regimens are commonly used in clinical practice. Our data highlight the importance of clinical–molecular selection for re-treatments and the need for prospective strategy trials in selected populations (2)
The clinical phase III trial, identified as NCT02394795 (PARADIGM), demonstrated that Panitumumab significantly enhanced ove…